Skip to main content

The TULIP-1 trial

Trial results published: TULIP-1 results fail to support phase II findings for anifrolumab in SLE

Monday 11 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA

Presenter: Richard Furie, Zucker School of Medicine at Hofstra/Northwell, New York, USA

In the phase III TULIP-1 study, patients with moderate-to-severe systemic lupus erythematosus were randomly assigned to receive intravenous anifrolumab – a human monoclonal antibody that binds the type I interferon receptor – at a dose of 150 mg or 300 mg every 4 weeks or placebo in addition to standard-of-care treatment.

The investigators will report efficacy and safety outcomes from the trial, including the primary endpoint of an SRI(4) response at 1 year.

Back to the ACR/ARP 2019 conference hub